Henry and Allison McCance Professor of Business Administration at HBS, Ethel Zimmerman Winer Professor of Public Policy and Director of Health Policy Research at Harvard Kennedy School of Government

Professor of Stem Cell and Regenerative Biology at Harvard University, Chief of Pathways Consult Service at Massachusetts General Hospital

Xander University Professor at Harvard University, Co-Director of Harvard Stem Cell Institute

Chris leads MPM Capital’s public market investing as portfolio manager for BioImpact Equities (formerly known as Burrage Capital) and the Oncology Impact Funds. Previously, Chris was a health care analyst at Fidelity Investments covering biotechnology, life-science tools and diagnostics, and she started her career as an analyst at MPM. She currently serves on the Harvard Medical School Board of Fellows and is a Trustee of the American Association for Cancer Research Foundation.

Dr. Enke Bashllari is a neuroscientist and venture investor. She is the Founder and Managing Director of Arkitekt Ventures, an early stage Health + Bio investment firm with the mission to improve and advance human health. Recognized by the Wall Street Journal as one of the Top Ten Women to Watch in Venture, Enke has been an early investor and advisor to over thirty transformational Health & Bio companies including Parsley Health, Tia, Sollis, CertifyOS, Cofertility and Nanite Bio. Enke serves on the Board of Directors of the Tisch MS Research Center of New York, and is a backer of First Close Partners, a fund that invests in underrepresented managers. Enke earned her PhD at Columbia University, and MBA at Harvard Business School where she was awarded the Kaplan Fellowship in life sciences.

Marc was named President and Chief Executive Officer of Thermo Fisher Scientific in 2009 after serving in multiple senior roles at the company. He became Chairman in 2020. Prior to joining Thermo Fisher, Marc served as President, Chief Executive Officer and a director of Kendro Laboratory Products. Previously, he worked for clinical diagnostics provider Dade Behring Inc., where he served as President – Americas. Marc began his career as a strategy consultant at Bain & Company and later joined Bain Capital. He serves on the boards Wesleyan University, Mass General Brigham, and the U.S.-China Business Council.

Hannah Chang is a Managing Director at Wu Capital, a global evergreen fund. Dr. Chang focuses on early-stage biopharmaceutical venture capital investments out of the firm’s San Francisco office. Representative investments include Semma Therapeutics (acquired by Vertex Pharmaceuticals), Korro Bio, Akouos (NASDAQ: AKUS), Gemini Therapeutics (NASDAQ: GMTX), Inipharm, and PACT Pharma.

She was previously an investment professional at 5AM Ventures where she helped found IDEAYA Biosciences (NASDAQ: IDYA) and served as a Board Observer for Crinetics Pharmaceuticals (NASDAQ: CRNX), among others. Earlier in her career Dr. Chang was a Project Leader at The Boston Consulting and a member of the Healthcare Practice.

Dr. Chang trained clinically in internal medicine and ophthalmology at the Beth Israel Deaconess Medical Center and Massachusetts Eye and Ear Infirmary, respectively. She is a licensed physician in the District of Columbia.

Sooah is a Partner focused on early stage investments in health & life sciences tech at SignalFire. SignalFire is an AI-native venture capital fund that has been building an in-house AI platform for the past decade with $2B+ AUM. Prior to SignalFire, she was a product leader at CVS Health, where she launched nationwide prescription delivery and virtual care products, and Devoted Health, currently valued at over $12 billion. At Underscore VC, she invested in fast growing B2B software startups, including life sciences tech products used by leading biopharma companies across the drug development cycle from R&D to commercial stages. She began her career at Michael Porter’s strategy firm where she advised healthcare & biopharma executives. Sooah has a joint-degree MBA | MPP from Harvard Business School and Harvard Kennedy School, where she worked with startup founders at the HBS Rock Center for Entrepreneurship and built her health & life sciences tech investment thesis as a Rock Venture Partner with Bain Capital. As a product builder, GTM strategist, and policy nerd turned investor, she partners with founders at the earliest stages of their discovery, building, and scaling journeys. She’s excited to reimagine how we develop, deliver, & pay for healthcare today and usher in a new era of AI-enabled health and longevity for all.

Paul has worked in the biotech industry for the last twenty-three years and spent fourteen years in the consumer products industry. He served as the Chief Financial Officer for Biogen from 2007 through 2017 and also served as the CFO at Alexion Pharmaceuticals from 2017-2019. At Biogen, Paul oversaw rapid growth in the company as it expanded it's products and pipeline. During his tenure as CFO, Biogen grew total return to shareholders at a 20% compound annual growth rate - the top decile of S&P 500 companies. He currently serves as a member of the Board of Directors at four life science companies, including Incyte Pharmaceuticals, Exact Sciences, Sionna Therapeutics and Xilio Therapeutics. He also serves on the Finance Committee for Catholic Charities of Boston. Paul is currently on the faculty at Cornell University’s graduate school of business where he teaches Corporate Finance. He is also an Executive Fellow at Harvard Business School serving as a guest speaker in finance classes, and providing support in the new Joint MS/MBA in Life Sciences program.

Dr. Andrew Dervan is Co-Founder & Chief Operating Officer at Cajal Neuroscience. Prior to Cajal, Andrew was a senior director of business development at Celgene (acquired by Bristol Myers Squibb in 2019). Andrew was responsible for a broad range of business development activities from search and evaluation through definitive document negotiation. He led several completed transactions in the areas of oncology and cell therapy. Andrew held previous roles in translational medicine at Celgene focused on leveraging novel single cell sequencing techniques for target discovery in oncology. Throughout his industry career, Andrew has continued to practice as a clinical geneticist at the University of Washington Medical Center.

Sean Doherty is the designer and chairman of the T1D Fund, an impact investment fund he co-founded in 2016 that has used a venture philanthropic model to catalyze over $700 million of private capital investment in type one diabetes (T1D) cure therapeutics. Sean has held a range of volunteer leadership positions for nearly 20 years at JDRF, the leading public charity in T1D. He is a former director of Provention Bio (NASDAQ: PRVB), which obtained approval for the first disease-modifying therapy in T1D and which has agreed to be acquired by Sanofi. Sean is currently a Fellow in Harvard’s Advanced Leadership Initiative. He is a former managing director of Bain Capital, a leading global alternative investment firm. As the firm’s first general counsel, he built an industry-leading legal, compliance and public affairs group and led a variety of efforts in crisis management, branding, and philanthropy. Earlier in his career, he was an attorney at Ropes & Gray LLP in Boston. He is a veteran of the United States Navy, in which he was an officer on a guided-missile frigate in the Middle East force in the early 1990s.

Adam Friedman is a physician-scientist and life sciences entrepreneur currently serving as President and Head of Corporate Strategy and Business Development for Scorpion Therapeutics, an oncology-focused precision medicine biotechnology company. He previously served as interim CEO and head of Corporate Development at Scorpion. Prior to helping to build Scorpion, Dr. Friedman was the Founder and CEO of Vivid Biosciences, an oncology discovery and development company. Previously an Entrepreneur-in-Residence at Atlas Venture, he helped to launch biotechnology companies exploring new areas of biology to alleviate human disease, including co-founding Raze Therapeutics, a next-generation metabolism company addressing fibrosis and cancer. Dr. Friedman trained clinically in pediatrics at Boston Children’s Hospital. He has authored multiple peer-reviewed publications in the fields of systems biology, cell signaling, genetics, and cancer biology.

Dr. Arjun Goyal is a Co-Founder and Managing Director of Vida Ventures, a leading US-based life sciences venture capital firm with a ~$1.8 billion in AUM. Arjun focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Arjun serves as a director on the boards of Scorpion Therapeutics, Quanta Therapeutics, Alterome Therapeutics and Centessa Pharmaceuticals (NASDAQ: CNTA) and as a co-founder and director, Affini-T Therapeutics. Furthermore, he has played key roles in Vida Venture’s investments in Homology Medicines (NASDAQ:FIXX), Pionyr Immunotherapeutics (acquired by Gilead), Peloton Therapeutics (acquired by Merck & Co.), and Asklepios Bio (acquired by Bayer). Before co-founding Vida Ventures in 2017, Arjun was a life sciences investor at 5AM Ventures. Arjun received his B.Sc. in Medical Science, Diploma in French and his MBBS degree from the Universities of Melbourne and Oxford. He completed his postgraduate clinical training in Internal Medicine in Sydney. He received his M.Phil. in Bioscience Enterprise from University of Cambridge and his MBA from Harvard Business School. Arjun has received multiple awards for his work including the Advance Award for Technology & Entrepreneurship from the Australian Government. He serves on the Committee for the American Australian Association Education Fellowship and is a Venture Capital Advisor at Harvard Business School.

Julia is Chief Operating Officer and Director of Investor Relations for Asha Therapeutics and Ibis Therapeutics. Asha Therapeutics is creating new therapeutic avenues through the modulation of normal biological pathways to reprogram cellular machinery through the development of de novo first-in-class compounds for neurodegenerative diseases and multiple cancers, including Parkinson's Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Ischemic Stroke, and Neuro-Oncology. A tech-bio company co-founded with Mayo Clinic, Ibis Therapeutics’ AI-driven Dynamic Fingerprint™ Platform engine enables the discovery of novel compounds and selection of patient cohorts using proprietary AI/physics-based screening of drug candidates against multiple binding modes on an array of disease-modifying and toxicity-causing protein targets and their variants. Julia was previously Director of Corporate Development and Strategy for Venn Therapeutics, a precision medicine company, and Head of Investor Relations for Aircastle (NYSE: AYR). Earlier in her career, Julia worked in investment banking at firms including JPMorgan and Credit Suisse.

Steve Hochberg is a co-founder and General Partner of Triatomic Capital Management. This venture capital firm was founded in 2022 with a focus on century defining technologies with potential cross-industry applications. Previously, Steve joined Deerfield Management, a global healthcare investment firm in 2013 to work on structured transactions in Deerfield’s Private Design Funds. As of today, Steve has remained involved with Deerfield as an Operating Partner, primarily in the capacity as a board member of select portfolio companies. Since graduation from business school in 1989, Steve has been a founder or co-founder of more than thirty companies. Steve is active in philanthropy as a Vice Chairman of the Mount Sinai Health System, a non-profit healthcare integrated delivery system in New York City with over $8 billion in annual revenues and he was previously the Chairman of the predecessor set of hospitals called Continuum. Steve graduated from the University of Michigan with a B.S., and he holds a master's degree in business administration (MBA) from Harvard.

Allie began her career at Celgene as an intern while she was an undergraduate biomedical engineering student. Though she started out in the lab, she soon realized that she was more interested in working on the strategy side of the company and moved to a role managing Celgene’s collaborations with biotechnology partners. After business school, Allie continued her career in business development at Regeneron Pharmaceuticals.

Sekar Kathiresan is co-founder and chief executive officer of Verve Therapeutics. He is also a member of the company’s board of directors. Verve is pioneering a new approach to the care of cardiovascular disease by developing single-course gene-editing therapies that safely and durably lower plasma LDL cholesterol in order to treat cardiovascular disease. Prior to joining Verve, he served as director of the Massachusetts General Hospital Center for Genomic Medicine as well as the Cardiovascular Disease Initiative at the Broad Institute and was professor of medicine at Harvard Medical School. For his contributions to understanding the inherited basis for cardiovascular disease, Dr. Kathiresan has been honored with a Distinguished Scientist Award from the American Heart Association.

Reshma is the Chief Executive Officer and President at Vertex Pharmaceuticals. She joined Vertex in 2017 and was previously the Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs. Prior to Vertex, Reshma spent more than 12 years at Amgen where she held a variety of roles across Research and Development, including as Vice President, Global Clinical Development, Nephrology & Metabolic Therapeutic Area and Vice President, U.S. Medical Organization, a group she established and grew to assume responsibility for the full portfolio of molecules. She is a member of the board of directors of the Biomedical Science Careers Program, an organization dedicated to supporting underrepresented students to pursue a career in STEM, and RIZE Massachusetts, a nonprofit foundation focused on ending the opioid epidemic. She is also a member of Boston University School of Medicine Dean’s Advisory Board.

Benjamine Liu is the co-founder and CEO of TrialSpark, a technology company reimagining drug development.

Benjamine received his DPhil at Oxford as a Rhodes Scholar, conducting his work with Sir Simon Lovestone. His doctoral thesis leveraged machine-learning, AI, and healthcare big-data -- genomics, proteomics, transcriptomics, metabolomics, imaging -- to develop diagnostics and therapeutics for Parkinson’s and Alzheimer’s disease.

During his graduate work, he observed the way clinical trials bottlenecked the development of new treatments for patients, compelling him to start TrialSpark. TrialSpark is a tech-driven drug development company that can run higher quality clinical trials at a fraction of the time and cost. TrialSpark partners with pharma companies and biotechs to develop drugs through in-licensing clinical stage pharmaceutical assets, NewCo formation, investing equity in companies, and forming unique strategic partnerships to develop therapeutics using our in-house clinical trial engine. Its ultimate mission is to bring new medicines to patients faster, more efficiently, and at lower cost.

Before TrialSpark, Ben graduated from Yale where he was awarded the college’s highest honor at graduation and received his MPhil with distinction in Computational Biology from the Department of Applied Mathematics and Theoretical Physics at Cambridge as a Paul Mellon Fellow.

Eileen is currently the CEO and co-founder of a biotechnology startup in stealth mode. She most recently served as Senior Vice President of Operations and Corporate Strategy at Vedere Bio prior to its acquisition by Novartis; Vice President of Portfolio Management at Potenza Therapeutics prior to its acquisition; and founding Senior Director, Program Management at Tizona Therapeutics. Eileen has over 20 years of experience in health care entrepreneurship, venture capital, marketing, and finance and has been involved with a number of Biologics, cell therapy and telehealth startups. Over her career, she has helped launch 15 products, in medical devices, therapeutics, and diagnostics. She has also participated in M&A and equity events totaling over $30bn.

Emily Minkow is a Venture Partner at RA Capital, where she focuses on creating and leading new biotech companies. Since joining RA, Emily has served as Interim CEO of Stylus Medicine, a stealth-stage genome engineering company, and contributed to the founding of and investment in several other companies in the genetic medicine, rare disease, immunology, and oncology spaces. Prior to joining RA, Emily was Chief Business Officer of Prevail Therapeutics, a gene therapy company focused on genetic forms of neurodegenerative disease, from the company’s inception in 2017 through its IPO and its acquisition by Eli Lilly in 2021. Previously, Emily spent over seven years at Celgene Corporation in positions of increasing responsibility in business development, in global marketing for the launch of Otezla for psoriasis and psoriatic arthritis, and as Principal to the Chairman and CEO. Emily started her career in strategy consulting at Frankel Group. She received a BA from Princeton University and an MBA from Harvard Business School.

Geoff is Senior Managing Director, Director of Therapeutics Research and a Senior Research Analyst at SVB Leerink covering Diversified Biopharmaceutical stocks. He has over 25 years of expertise in advisory, executive and investment roles in the biopharmaceutical industry. Prior to joining SVB Leerink, Geoff established biotechnology research coverage at Sanford C. Bernstein, served as Director of Life Sciences and Chief Operating Officer at BTG PLC and previously served in a variety of positions at Merck & Co, including Head of Worldwide Marketing in the Vaccine Division. Geoff has been consistently ranked as one of Wall Street’s most influential biotechnology analysts.

Evan is a Principal at Blackstone Life Sciences. Before joining Blackstone, Evan was the Head of Strategy at Moderna (NASDAQ: MRNA). Before joining Moderna, Evan was a Principal at Bain Capital Ventures and an Engagement Manager at McKinsey & Company in New York.

Kareem is the Chief Business Officer at ElevateBio and Chief Operating Office at LifeEDIT and has more than ten years of experience building partnerships and executing a range of deals in the cell and gene therapy space. Prior to ElevateBio, Kareem was Head of Business Development and Corporate Strategy at Evelo Biosciences. He played an integral role in the company’s $85 million initial public offering (IPO) and private Series B and C fundraising rounds. At Celgene, he executed over a dozen deals with a total value greater than $5 billion and actively partnered with the science team to develop a cancer immunotherapy strategy which ultimately guided Celgene into the rapidly developing field of immuno-oncology (IO). Kareem started his career at Vertex Pharmaceuticals in formulation development.

Mark Robinson has over 25 years of investment banking experience, advising many of the most prominent pharmaceutical, biotechnology, and medical device companies in the healthcare industry.

Mark is a Partner at Centerview Partners, one of the largest privately-held independent invesrment banks. Previous to him joining Centerview, Mark was responsible for the global healthcare investment banking practice at Merrill Lynch. During his tenure, Merrill Lynch was the leading equity financier for the biotechnology industry. Additionally, he advised on many notable industry transforming transactions including representing Immunex, the maker of Enbrel, in its $16 billion sale to Amgen, IDEC in its merger with Biogen to create BiogenIdec, Boston Scientific in its $25 billion hostile acquisition of Guidant, Vertex in its acquisition of Aurora and Illumina in its purchase of Solexa.

Since joining Centerview in 2009, the firm has been a leading advisor to the global Biopharmaceutical industry most notable representing biotechnology companies on strategic defense. In the period from 2019 to 2021, Centerview represented 18 companies in transactions where the selling price exceeded $1 billion. Immumedics, MyoKardia and Array Biopharma were some of the most prominent clients.

Mark serves on the Board of the College of Letters and Science at U.C. Berkeley and is a member of the Board of Trustees of the U.C. Berkeley Foundation. Under his guidance, the Robinson Program in Life Science Business and Entrepreneurship, a joint undergraduate degree combining Business and Biological Sciences was established at Berkeley in 2018. He is also a Trustee of The Thacher School, as well as a member of the Council on Foreign Relations.

Howie is an independent consultant and serves on the board of directors of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), where he served as CEO from 2015 to 2017, Aria Pharmaceuticals, Inc., Entrega, Inc., Hammerton, Inc., and Kala Pharmaceuticals, Inc. (NASDAQ: KALA) where he served as Chairman from 2014 to 2016. From 2004 to 2008, he was Vice President, Commercial Strategy at Gilead Sciences, Inc. where his responsibilities included strategic marketing, global brand management, health economics, competitive intelligence, market research and Gilead’s overall portfolio and business planning.

Prior to joining Gilead, Howie was President of ALZA Corporation where he was responsible for all aspects of managing ALZA as an independent 1000-person operating company within the Johnson & Johnson Family of Companies. Previously at ALZA as Vice President, Product Development, he was responsible for product development activities, portfolio management and corporate and new product planning. Over his 10 years at ALZA, Mr. Rosen also had responsibilities for mergers and acquisitions, R& D planning, and technology ventures. Prior to joining ALZA, Mr. Rosen managed the west coast practice of Integral, Inc., was Director, Corporate Development at GenPharm International, Inc. and was a consultant in the San Francisco office of McKinsey & Co.

Mr. Rosen is a Lecturer in the Department of Chemical Engineering at Stanford and a Lecturer in Management at the Stanford Graduate School of Business. He is also a member of the National Academy of Engineering (NAE), where he is a Councilor and a Trustee of the NAE Foundation, and a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). He is co-inventor on 7 US patents.

Christy is the Chief Commercial Officer of Blueprint Medicines and also serves on the board of directors of Xilio Therapeutics. She has more than 20 years of global pharmaceutical and biotechnology experience. Prior to joining Blueprint Medicines, she served as the Multiple Sclerosis (MS) Business Unit Head, North America, at Sanofi Genzyme. In this role, she oversaw all aspects of the financial performance of Sanofi Genzyme’s MS franchise and increased market share for existing products, led the launch of new therapies and optimized operations to accelerate patient access. Previously, Christy served as Vice President, MS Sales, and Vice President, MS Patient and Provider Services, at Sanofi Genzyme. Prior to joining Sanofi Genzyme, she held various roles at Biogen Inc., including Head, Commercial Strategy for Eidetica Biopharma GmbH, Biogen’s biosimilar-focused venture, and U.S. Brand Leader for TYSABRI® (natalizumab). In addition, she consulted in the healthcare practice at the Boston Consulting Group.

Wayne is CEO and co-founder of Estuary Biotherapeutics, an early-stage biotechnology startup. Wayne has additionally served as a business advisor to early-stage companies, including Sardona Therapeutics and Opus Genetics. Most recently, Wayne was at MyoKardia, where he joined in 2015 prior to MyoKardia’s IPO. At MyoKardia, Wayne held roles of increasing responsibility, culminating in his position as Head of Business Development and Corporate Strategy until Bristol Myers Squibb’s acquisition in 2020 of MyoKardia for $13.1 billion. In this role, he led licensing, partnering and M&A activities as well as the corporate strategy and competitive intelligence functions. Additionally, at various points during his time at MyoKardia, Wayne led and served as a key contributor to the portfolio strategy, investor relations, corporate communications, capital markets, and finance functions. Prior to MyoKardia, he held operating, investing, or finance roles at Silk Road Medical, American Infrastructure Funds, RBC Capital Markets, and Valero. Wayne is an active volunteer with the Foundation Fighting Blindness. Wayne holds an MBA from Harvard Business School and a B.S. with honors in chemical engineering from the University of California, Berkeley.

Shalini has more than 25 years of financial and corporate strategy experience in the life sciences industry. Most recently, she was the Chief Financial Officer (CFO) at Ultragenyx where she was responsible for leading the company's corporate finance, strategy, and information technology functions. Prior to Ultragenyx, Ms. Sharp was CFO at Agenus Inc., and before that, she worked in corporate strategy at Elan Pharmaceuticals and in management consulting at McKinsey. Shalini serves as a board member of Organon, Mirati Therapeutics, Neurocrine Biosciences, Precision Biosciences, Sutro Biopharma and TB Alliance. She previously served on the boards of Array BioPharma, Panacea Acquisition Corporation and Agenus.

David is the founder of Astounding HealthTech Advisory Services and serves a trusted advisor and experienced thought partner to senior R&D leaders as they work through the challenges of effectively leveraging emerging digital and data opportunities in the context of complex pharmaceutical and healthcare organizations. David completed medical training at MGH and conducted postdoctoral research with Doug Melton at the Harvard Stem Cell Institute. He then embarked on a private sector career as Chief Medical Officer at DNAnexus and as a Senior Partner at Takeda Ventures. David has also written extensively about medicine, innovation, technology, and business for a range of popular publications, and since 2015 has co-hosted the popular Tech Tonics podcast.

Chris Shumway has invested in, advised and built growth businesses for over 25 years. As the Managing Partner of Shumway Capital, he oversees the firm’s investments in a wide range of long-term, high-growth businesses.

As an entrepreneur himself, Chris understands the passion, vision and execution required to achieve sustainable growth. He grew Shumway Capital from $70 million of assets under management to over $9 billion of capital and the firm was recognized numerous times as a top industry performer. Chris has helped many growing businesses with his operational and strategic advice and experience. He has also provided seed capital to a number of “new paradigm” business models that have grown into successful firms.

Prior to founding Shumway Capital, Chris joined Tiger Management while finishing business school and was named a Senior Managing Director and Management Committee member at age 30.

He received a B.S. from the McIntire School of Commerce at the University of Virginia and an M.B.A. from Harvard Business School. He currently serves as Chairman of the Board of Finch Therapeutics, a Boston based biotechnology firm. He is also a member of the boards of the McIntire School of Commerce Foundation (University of Virginia), the Stamford School for Excellence and The Shumway Foundation. In addition, Chris serves as a Visiting Scholar at the University of Virginia, teaching global macroeconomics and investing.

Chris is a long-time supporter of and advocate for a range of charitable causes. As a strong proponent of education reform, he established The Shumway Foundation with the primary goal of helping to break the cycle of poverty through better opportunities in education.

Jan is an Executive Chairman at DEM Biopharma, and a member of the Board of Directors at Zentalis Pharmaceuticals (Nasdaq:ZNTL) and Monte Rosa Therapeutics (Nasdaq:GLUE). Previously, he was the CEO of Trillium Therapeutics (Nasdaq:TRIL), a clinical stage immuno-oncology company, where he led a highly successful, 360-degree turn-around that produced a leading CD47 drug candidate, while taking the company from a $16M valuation to a $2.3B buy-out by Pfizer in two years. Prior to that, Jan was the CEO of Tal Medical, a private, clinical stage neuroscience company; a partner in the life sciences practice at Bain & Company, Boston; and a manager at Price Waterhouse Corporate Finance in London, UK and Vienna, Austria.

Peter was a Commercial, M&A, and Strategy executive at J&J for 30 years and is now working with a cadre of medtech and digital (operative AR, RCM, and sales targeting SaaS) companies, including as Executive Chair of neurosurgical tissue engineering firm Nurami Medical. Potentially relevant examples of clinical fields include Open and MI approaches to Surgery, Orthopedics, and Neuro as well as Injectables, Cell based cartilage therapies and Neuromodulation. He is active in industry organizations like MassMEDIC and HBS Healthcare Alumni Association.

Satish is a serial entrepreneur in the life sciences and healthcare sectors. His main interests lie in Healthcare IT and at the intersection of drug, medical device and diagnostics development, and software systems development, primarily for accelerating clinical trials and regulatory approvals. Satish’s current venture, Trove Health (mytrovehealth.com), focuses on building technology for the engagement and retention of patients in clinical trials. Prior to Trove Health, Satish founded a number of companies focused on developing technology products or services within life sciences R&D: Avigo Solutions (Managing Partner), Virtify (Founder and CEO), Tribiosys (Co-Founder) and Enmed (Co-Founder and CEO). Early in his career, Satish was the Director of the Imaging Lab at EPIX Medical, and also worked as a lead Engineer at Hewlett-Packard Medical Products Group, working on developing innovative MRI, Ultrasound, and Telemedicine products. Satish Tadikonda is a Senior Lecturer in the Entrepreneurial Management Unit at Harvard Business School. He teaches The Entrepreneurial Manager, a required first-year MBA course, and Entrepreneurship in the Life Sciences, an elective course for second-year students.

Jim is the founder and chief executive officer of Foresite Capital, a U.S.-focused healthcare investment firm founded in 2011 that has approximately $4 billion in assets under management. During the last three decades Jim has been a thought partner for some of the most impactful and fastest growth companies of their generation including: 10x Genomics (Nasdaq: TXG), Amerigroup (Nasdaq: ANTM), and Jazz Pharmaceuticals (Nasdaq: JAZZ). Jim’s first success came while he was still at HBS, when he co-founded GelTex Pharmaceuticals and brought two drugs to market. Jim was the founding chief executive of Theravance, Inc. His investment experience includes being a co-founder of Prospect Ventures and, earlier in his career, a partner of Sierra Ventures, where he established its healthcare services investment practice.

Courtney Wallace is a Venture Partner at Third Rock Ventures, where she focuses on the creation, development, and strategy of new biotechnology companies. Prior to Third Rock, Courtney was an early employee and the Chief Business Officer of Beam Therapeutics. As part of the executive leadership team, she helped lead the company through several important milestones, including advancing programs from discovery stage into the clinic, executing the company’s initial public offering, and implementing partnerships to accelerate the development of precision genetic medicines. She also contributed to the early company builds of several Beam partners, including Prime Medicine and Orbital Therapeutics. Prior to Beam, Courtney was in positions of increasing responsibility at Celgene Corporation, where she was responsible for leading collaborations, licensing transactions, equity investments, and mergers and acquisitions across a variety of therapeutic areas. Earlier in her career, Courtney was a consultant for Easton Associates, where she advised biotechnology and pharmaceutical companies on general corporate strategy, pipeline and portfolio planning, clinical development, sales and marketing activities, and business development. Courtney holds an MBA from Harvard Business School and an AB from Harvard College. Courtney is also an independent board director for Kezar Life Sciences, a clinical stage biotechnology company advancing treatments for patients with autoimmune diseases and cancer.